



# Implications of childhood hypercholesterolemia

RICHARD E. GARCIA, MD AND DOUGLAS S. MOODIE, MD

■ Several studies have documented that hypercholesterolemia is common in American children. Other studies have shown that elevated cholesterol levels in childhood remain elevated well into adult life. Autopsy studies of adolescents have also found a strong positive correlation between antemortem cholesterol levels and early atherosclerotic changes in their aortas and coronary arteries. Collectively, these studies provide strong and consistent evidence that atherosclerosis begins in childhood. The evidence is also overwhelming that lowering elevated low density lipoprotein cholesterol levels reduces the risk of heart attacks caused by coronary heart disease, at least among middle-aged men. As a result, routine cholesterol and coronary heart disease risk factor surveillance in childhood is both productive and appropriate. Premature coronary heart disease may be largely preventable and atherosclerosis, if not preventable, can be significantly delayed.

□ INDEX TERM: HYPERCHOLESTEROLEMIA, PEDIATRIC □ CLEVE CLIN J MED 1990; 57:715-720

**C**ARDIOVASCULAR disease is the eventual cause of death for nearly half of the U. S. population. This fact remains despite a 40% decline during the past 30 years in the age-adjusted mortality rate from cardiovascular disease.<sup>1,2</sup> The decreasing coronary heart disease mortality can be attributed to several medical interventions: improved identification and treatment of hypertension, increased surveillance of heart disease risk factors, and advances in specialized coronary care units.<sup>3</sup> In addition, the American public has become increasingly aware of health and physical fitness, and millions of adults have stopped cigarette smoking.

Symptomatic heart disease still affects 5.4 million people in the United States, and 1.5 million will ex-

perience a myocardial infarction in the coming year.<sup>4,5</sup> According to the Framingham Heart Study, 20% of men and 6% of women have coronary heart disease by age 60.<sup>6</sup> In addition, 6.7% of men and women eventually have a cerebrovascular accident.

Atherosclerosis is associated with several risk factors. Those that are modifiable include cigarette smoking, hypertension, obesity, physical inactivity, hypercholesterolemia, and diabetes. Nonmodifiable risk factors include age, male sex, and a family history of premature atherosclerotic disease or known hyperlipidemia. Hypercholesterolemia is the most basic and fundamental of the recognized risk factors.<sup>7</sup>

The evidence to support the cholesterol hypothesis is compelling.<sup>8</sup> The incidence of coronary heart disease increases as low density lipoprotein (LDL) cholesterol levels increase.<sup>9</sup> An expanding body of evidence indicates that lowering LDL cholesterol levels in hypercholesterolemic adults will reduce the incidence of coronary heart disease.<sup>9-14</sup>

From the Departments of Primary Care (R.E.G.) and Pediatrics (D.S.M.), The Cleveland Clinic Foundation.

Address reprint requests to R.E.G., Department of Primary Care, The Cleveland Clinic Foundation, One Clinic Center, 9500 Euclid Avenue, Cleveland, Ohio 44195.

**TABLE 1**  
EXPECTED DISTRIBUTION OF SERUM LIPID LEVELS, NORMAL  
CHILDREN 3 TO 19 YEARS OLD

Lipid type	5th percentile (mg/dL)	Mean (mg/dL)	95th percentile (mg/dL)
TC	120	160	200
LDL-C	65	100	130
HDL-C	35	55	70
TG	35	75	110

TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides.

#### EARLY ONSET OF ATHEROSCLEROSIS

Keys showed in 1975 that increases in dietary fat and cholesterol are accompanied by increases in the frequency of coronary heart disease around the world.<sup>15</sup> Countries without significant hyperlipidemia have a low incidence of cardiovascular disease. Keys commented that the greatest likelihood of success in preventing coronary heart disease lay in the control of risk factors at early ages.

Thirty years ago, Holman<sup>16</sup> documented the existence of fatty streaks in the aortas of nearly all American children over 3 years of age who were studied. He urged that atherosclerosis be considered a pediatric nutritional problem. Stryer<sup>17</sup> noted fatty streaks in the coronary arteries of half the children 10 to 14 years old at autopsy; one third had macrophage foam cells in the intima of their coronary arteries. Seventy-seven percent of soldiers in their early 20s who were killed in the Korean and Vietnam wars had significant coronary atherosclerosis, and 5% had advanced coronary artery disease.<sup>18,19</sup> With increasing age and risk factor acquisition, these fatty streaks become fibrous plaques, which become advanced lesions.<sup>20</sup> These studies provide strong and consistent evidence that atherosclerosis begins in childhood.

#### HYPERCHOLESTEROLEMIA IN CHILDHOOD

Hypercholesterolemia is common in childhood. The Lipid Research Clinics program surveyed the plasma lipid and lipoprotein levels of 60,502 adults and children in 10 North American locations to obtain reference values for the US population.<sup>21,22</sup> Table 1 contains the expected distribution of serum lipid levels for US children 3 to 19 years of age, based on the Lipid Research Clinics<sup>21,22</sup> and Bogalusa Heart Study<sup>23,24</sup> data.

The Bogalusa Heart Study<sup>23,24</sup> is an ongoing epidemiologic review of cardiovascular disease risk fac-

tors among Louisiana youth from birth through age 26. This study has provided lipid and risk factor data from 10,000 healthy, young individuals. Autopsies of adolescents (mean age, 18 years) from Bogalusa who died from such causes as accidents, homicides, and suicides, show a strong positive correlation between antemortem blood pressure and cholesterol levels and postmortem fatty streaks in the aortas and coronary arteries.

Several lipid surveillance studies,<sup>25,26</sup> including one of 6,500 children in a private practice setting in Parma Heights, Ohio,<sup>27</sup> have found nearly twice the expected number of children to have serum cholesterol levels above the 95th percentile (200 mg/dL). Cholesterol levels may vary considerably in different parts of country, depending on regional variations in dietary preferences and habits.

Elevated cholesterol levels in children beyond 2 to 3 years of age tend to remain high in adult life. The Muscatine Study<sup>28</sup> tested 2,446 young people at ages 8 to 18 and again at ages 20 to 30 for cholesterol levels and other cardiac risk factors. Ten years later, 43% of those children with initial cholesterol levels above the 90th percentile were still above the 90th percentile; 62% were above the 75th percentile, and 81% were above the mean. The Bogalusa Heart Study reported similar findings: more than 70% of children with elevated cholesterol levels remained hypercholesterolemic 12 years later.<sup>29</sup>

Orchard and colleagues<sup>30</sup> studied 611 individuals found to be hypercholesterolemic at age 12. At 21 years of age, 70% of the 611 subjects were still in the top two quintiles for cholesterol concentration. The statistical likelihood of remaining in a particular quintile over time due to chance alone is 20%. These data provide convincing evidence that the major predictor of adult hypercholesterolemia is hypercholesterolemia in childhood.

#### GENETIC CAUSES OF HYPERCHOLESTEROLEMIA

Genetic make-up strongly influences how individuals interact with environmental risk factors in the evolution of atherosclerotic heart disease. An estimated 5% of American children have a genetic predisposition for hypercholesterolemia and are therefore at increased risk for premature coronary heart disease.<sup>31</sup> Fifty to eighty percent of individuals who have coronary heart disease before age 55 have hyperlipidemia.<sup>32</sup> Clearly, modifiable coronary heart disease risk factors play an important role in premature coronary heart disease. The relative importance of genetics and environmental factors in the cause of hypercholesterolemia remains controversial.<sup>7,33-38</sup>

Several genetic lipid disorders can surface during childhood. Among the most common are familial hypercholesterolemia, familial combined hyperlipidemia, and polygenic hypercholesterolemia.<sup>32</sup>

Familial hypercholesterolemia (FH) occurs in 0.2% to 0.5% of the population. The heterozygous offspring has half the normal number of LDL receptor sites on cell membranes.<sup>39</sup> The condition is an autosomal dominant disorder and affects 4% of those patients with a cholesterol level above the 95th percentile (200 mg/dL). Ninety percent of such individuals have a myocardial infarction by age 60, and most have tendon xanthomas, corneal arcus, or xanthelasmas. It is the most common monogenic disorder in our society that eventually produces morbidity and mortality. Serum cholesterol is often twice the normal value, and half of first-degree relatives may also have the disorder. Individuals who are homozygous for the FH gene have essentially no LDL receptors. Plasmapheresis and liver transplantation, along with dietary and drug therapy, are usually necessary to reduce their cholesterol levels.

Familial combined hyperlipidemia, another autosomal dominant disorder, affects 1% to 2% of the American population.<sup>40</sup> Approximately 20% express the disease in childhood.<sup>41</sup> The underlying abnormality is probably caused by overproduction of very low density lipoprotein/apolipoprotein B (VLDL/Apo B) particles by the liver.<sup>42</sup> A third of such patients have hypertriglyceridemia, a third have hypercholesterolemia, and a third have both. Hypertriglyceridemia seems to occur early in childhood, whereas hypercholesterolemia occurs later in life. Familial combined hyperlipidemia can be diagnosed when multiple lipoprotein phenotypes are found in a single family.

Polygenic hypercholesterolemia occurs in approximately 1% of the population. The disorder may represent one or possibly combinations of several genetic defects that adversely affect LDL cholesterol metabolism. There may be an acquired deficiency of LDL receptors, but if so, it is not as severe as the deficiency in familial hypercholesterolemia. Cholesterol elevations are more moderate, and the relationship of cholesterol values among various relatives is approximately half what would be expected from a purely genetic origin.<sup>32</sup> Such individuals may be more sensitive to environmental risk factors, such as increased dietary saturated fat and cholesterol,<sup>34</sup> smoking, and sedentary lifestyle.

A low level of high-density lipoprotein (HDL) cholesterol is a strong and independent risk factor for coronary heart disease. Isolated low level HDL cholesterol levels (<35 mg/dL) may occur in 3% of the

general population.<sup>32</sup> Possible causes include environmental factors, such as smoking, excessive alcohol consumption, and obesity. Some individuals have low HDL cholesterol because they have an autosomal dominant disorder<sup>43</sup> with incomplete penetrance that interferes with Apo A-I and Apo A-II metabolism.

---

#### SCREENING FOR HYPERCHOLESTEROLEMIA

---

Routine screening of children has shown that from 8% to 10% have cholesterol levels that exceed the Lipid Research Clinics' 95th percentile of 200 mg/dL. Assuming that 5% of children are genetically predisposed to premature coronary heart disease,<sup>31</sup> and that many will not manifest hypercholesterolemia until adult life, then approximately half of childhood hypercholesterolemia is caused by environmental factors—primarily diet.<sup>44,45</sup>

A recent report of 500 hypercholesterolemic children (mean age, 8 years) revealed that 85% had a definable phenotypic lipid disorder.<sup>46</sup> Only 5% (25) were identified as being hypercholesterolemic because they had HDL cholesterol levels above the 95th percentile and therefore were not at risk of future coronary heart disease. Thirty-two percent (160) of them had a primary or secondary relative with a premature myocardial infarction. These data support universal cholesterol surveillance in childhood and lipid profiles for those with total cholesterol levels above 200 mg/dL.

Pediatric cardiologists are beginning to identify families who are at increased risk for premature coronary heart disease. A family at risk is one with any member who has high LDL cholesterol concentration, a low HDL cholesterol concentration, coronary heart disease before age 55, essential hypertension, or who is 30% above ideal weight, or who smokes cigarettes.<sup>47</sup>

The National Heart Lung and Blood Institute and the National Institutes of Health's Office of Medical Applications of Research, as a result of a consensus conference in 1984,<sup>48</sup> concluded that lowering high LDL cholesterol levels reduces the risk of heart attack from coronary heart disease. The National Cholesterol Education Program has published guidelines for the detection and treatment of hypercholesterolemia in adults.<sup>49</sup> Currently, a panel of experts of the National Cholesterol Education Program is considering similar guidelines for children. Their report is expected to be released later this year.

The American Heart Association's Committee on Atherosclerosis and Hypertension in Childhood recommends that all children gradually decrease their consumption of cholesterol and saturated fat and that risk-

factor surveillance and advice regarding prudent lifestyle choices be provided to all children.<sup>45</sup> The Committee on Nutrition of the American Academy of Pediatrics recommends dietary changes<sup>50</sup> but currently advocates cholesterol screening only for children from high-risk families<sup>51</sup> (those with known hyperlipidemia or premature coronary heart disease). The American Heart Foundation recommends universal cholesterol surveillance after 2 years of age and dietary modification for the entire population to lower cholesterol consumption.<sup>4</sup>

---

#### TREATMENT ISSUES

---

Children older than 2 years would benefit from the American Heart Association's Step I Diet, in which less than 30% of calories come from fat and less than 10% of calories come from saturated fat. Cholesterol consumption is limited to 100 mg per 1,000 kilocalories (less than 300 mg/day), and total calories are adjusted to maintain ideal weight. Limiting dietary saturated fat and cholesterol should cause no harm because cholesterol can be synthesized by the liver and the only essential fatty acids are polyunsaturated.<sup>8</sup> Frequent coronary heart disease risk factor surveillance, routine blood pressure monitoring, and advice regarding prudent lifestyle choices, such as avoiding cigarettes, adopting weight control measures, and regular physical activity, should be routine preventive health care for all American children and their families.<sup>52-54</sup>

Drug therapy for childhood hypercholesterolemia is more controversial and has been predominated by the bile-acid binding resins, cholestyramine and colestipol. Their long-term safety is generally accepted.<sup>55</sup> Drug therapy alone can achieve mean reductions of 20% in LDL cholesterol levels.<sup>56</sup> Gastric distress and constipation are not common side effects in children, in contrast to adults. Serum fat-soluble vitamins and folic acid may be monitored during therapy with resins, although levels associated with deficiency have not been observed.<sup>57</sup> Compliance is difficult because the drugs are not palatable.

For children 10 years old or older with a family history of premature coronary artery disease and in whom monotherapy is inadequate, niacin may be given in combination with cholestyramine. Niacin reduces LDL cholesterol and triglycerides, increases HDL cholesterol, and is inexpensive. Niacin is potentially hazardous, however, because of stomach irritation, flushing of the

skin and, most importantly, liver toxicity. Therefore, careful monitoring of liver function is imperative during niacin therapy so that the drug can be stopped at the first sign of toxicity. The adverse effects clear when the drug is stopped. Combination therapy with cholestyramine and niacin can reduce LDL cholesterol levels by approximately 35%.<sup>56</sup> Inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, such as lovastatin, should be prescribed cautiously in childhood because the long-term effects of drugs that inhibit metabolic pathways are unknown. More information and new medications are needed to make possibly lifetime pharmacotherapy reasonable for the at-risk pediatric population.

---

#### CONCLUSION

---

Dietary modification for the entire population after 2 years of age to reduce intake of cholesterol and saturated fat intake appears entirely appropriate. Universal cholesterol screening of all children after 2 years of age is supported by the studies reported in this review.<sup>7,23,25,27,30,47</sup> In general, children who have LDL levels greater than 160 mg/dL and at least two other risk factors, or LDL levels greater than 190 mg/dL with or without risk factors, may be candidates for more intensive dietary manipulation and possibly pharmacotherapy. These children also may need referral to pediatric hyperlipidemia clinics.

Children from high risk-families are in a special risk group; these children and should routinely have lipid profiles rather than simple cholesterol screening. When the family history shows premature coronary heart disease and a specific diagnosis is unclear, specialized studies may be appropriate, such as measurement of Lp(a),<sup>58</sup> HDL-2,<sup>47</sup> Apo A-I, and Apo B levels.<sup>59,60</sup>

Molecular biologists and geneticists will clarify many lipid disorders in the future. The US Preventive Services Task Force has stated that, "Abundant evidence documents that the majority of deaths among Americans under age 65 are preventable, many through interventions best provided in a clinician's office."<sup>61</sup> Premature coronary heart disease may be largely preventable. Atherosclerosis can be significantly delayed, if not prevented.

With respect to whether or not atherosclerosis begins in childhood, Milton's statement<sup>62</sup> may be remarkably prescient: "Childhood shows the man as morning shows the day."

## REFERENCES

- Feinleib M. The magnitude and nature of the decrease in coronary heart disease mortality rate. *Am J Cardiol* 1984; **54**:2C-6C.
- Wilson PWF. The epidemiology of hypercholesterolemia. A global perspective. *Am J Med* 1989; **87**(Suppl 4A):55-135.
- Levy RI. Causes of the decrease in cardiovascular mortality. *Am J Cardiol* 1984; **54**:7C-13C.
- Wynder EL. Cholesterol: a pediatric perspective. American Health Foundation Monograph, Coronary Artery Disease Prevention. *Prev Med* 1989; **18**:323-409.
- American Heart Association. 1987 Heart Facts. Dallas, Tex: American Heart Association; 1987.
- Castelli WP. Epidemiology of coronary heart disease: the Framingham heart study. *Am J Med* 1984; **76**(2A):4-12.
- Arden MR, Jacobson MS. The prevention and treatment of atherosclerosis: the new preventive pediatrics. *Childrens Hospital Quarterly* 1989; **1**:5-10.
- Kwiterovich PO Jr. Biochemical, clinical, epidemiologic, genetic, and pathologic data in the pediatric age group relevant to the cholesterol hypothesis. *Pediatrics* 1986; **78**:349-362.
- Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the multiple risk factor intervention trial (MRFIT). *JAMA* 1986; **256**:2823-2828.
- The Lipid Research Clinics Coronary Primary Prevention Trial results II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. *JAMA* 1984; **251**:365-373.
- The Lipid Research Clinics Coronary Primary Prevention Trial results I. Reduction in incidence of coronary heart disease. *JAMA* 1984; **251**:351-361.
- Gotto AM. Diet and cholesterol guidelines and coronary heart disease. *J Am Coll Cardiol* 1989; **13**:503-507.
- Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham Study. *JAMA* 1987; **257**:2176-2180.
- Frick MH, Elo O, Haapa K, et al. Helsinki heart study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. *N Engl J Med* 1987; **317**:1237-1245.
- Keys A. Coronary heart disease—the global picture. *Atherosclerosis* 1975; **22**:149-192.
- Holman R. Atherosclerosis—a pediatric nutritional problem? *Am J Clin Nutr* 1961; **9**:565-569.
- Stary HC. Macrophages, macrophage foam cells, and eccentric-intimal thickening in the coronary arteries of young children. *Atherosclerosis* 1987; **64**:91-108.
- Enos WF, Holmes RH, Boyer J. Coronary disease among United States soldiers killed in action in Korea: preliminary report. *JAMA* 1953; **152**:1090-1093.
- McNamara JJ, Molot MA, Stremple JF. Coronary artery disease in combat casualties in Viet Nam. *JAMA* 1971; **216**:1185-1187.
- Ross R. The pathogenesis of atherosclerosis—an update. *N Engl J Med* 1986; **314**:488-497.
- Rifkind BM, Segal P. Lipid Research Clinics program reference values for hyperlipidemia and hypolipidemia. *JAMA* 1983; **250**:1869-1872.
- Lipid Research Clinics. Population studies data book. Vol I: The Prevalence Study. Department of Health and Human Services (NIH) 80-1527; 1980.
- Newman WP, Freedman DS, Voors AW, et al. Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis. The Bogalusa Heart Study. *N Engl J Med* 1986; **314**:138-144.
- Berenson GS, Srinivasan SR, Mac D, Hunter S, et al. Risk factors in early life as predictors of adult heart disease: The Bogalusa Heart Study. *Am J Med Sci* 1989; **298**:141-151.
- Davidson DM, Bradley BJ, Landry SM, Iftner CA, Bramblett SN. School-based blood cholesterol screening. *J Pediatr Health Care* 1989; **3**:3-8.
- Walter HJ, Hofman A. Socioeconomic status, ethnic origin, and risk factors for coronary heart disease in children. *Am Heart J* 1987; **113**:812-818.
- Garcia RE, Moodie DS. Routine cholesterol surveillance in childhood. *Pediatrics* 1989; **84**:751-755.
- Lauer RM, Lee JL, Clarke WR. Factors affecting the relationship between childhood and adult cholesterol levels: the Muscatine Study. *Pediatrics* 1988; **82**:309-318.
- Webber LS, Srinivasan SR, Berenson GS. Tracking of serum lipids and lipoproteins over 12 years into young adulthood—The Bogalusa Heart Study (abstract). *Circulation* 1988; **78**(suppl 2):II-481.
- Orchard TJ, Donahue RP, Kuller LH, Hodge PN, Drash AL. Cholesterol screening in childhood: Does it predict adult hypercholesterolemia? The Beaver County experience. *J Pediatr* 1983; **103**:687-691.
- Whelan EM, Stare FJ. Nutrition. *JAMA* 1990; **263**:2661-2663.
- Motulsky AG. Current concepts in genetics. The genetic hyperlipidemias. *N Engl J Med* 1976; **294**:823-827.
- Rahimtoola SH. Cholesterol and coronary heart disease: a perspective. *JAMA* 1985; **253**:2094-2095.
- Grundy SM, Vega GL. Causes of high blood cholesterol. Research advances series. *Circulation* 1990; **81**:412-427.
- Steinberg D. The cholesterol controversy is over. Why did it take so long? *Circulation* 1989; **80**:1070-1078.
- Jacobson MS, Lillienfeld DE. Current literature and clinical issues. The pediatrician's role in atherosclerosis prevention. *J Pediatr* 1988; **112**:836-841.
- Lee J, Lauer RM, Clarke WR. Lipoproteins in the progeny of young men with coronary artery disease: children with increased risk. *Pediatrics* 1986; **78**:330-337.
- Prevention of adult atherosclerosis during childhood. Report of the 95th Ross Conference on Pediatric Research; Sept. 20-22, 1987; Tuscaloosa, Ala.
- Goldstein JL, Brown MS. Familial hypercholesterolemia. In: Stanbury JB, ed. *Metabolic Basis of Inherited Disease*, 5th ed. New York: McGraw-Hill Book Co; 1983:672-712.
- Glueck CJ, Fallar R, Buncher CR, Tsang R, Steiner P. Familial combined hyperlipoproteinemia studies in 91 adults and 95 children from 33 kindreds. *Metabolism* 1973; **22**:1403-1420.
- Breslow JL. Pediatric aspects of hyperlipidemia. *Pediatrics* 1978; **62**:510-520.
- Kwiterovich P, Berenson GS. Pediatrics and cholesterol-related issues. *Lipid Letter* 1989; **6**(2).
- Third JHLC, Montag J, Flynn M, Freidel J, Laskarzewski P, Glueck CJ. Primary and familial hypoalphalipoproteinemia. *Metabolism* 1984; **33**:136-146.
- Weidman WH. Cardiovascular risk modification in childhood: hyperlipidemia. *Mayo Clin Proc* 1986; **61**:910-913.
- Diagnosis and treatment of primary hyperlipidemia in childhood. A joint statement for physicians by the Committee on Atherosclerosis and Hypertension in Childhood of the Council of Cardiovascular Disease in the Young and by the Nutrition Committee, American Heart Association. *Circulation* 1986; **74**:1181A-1188A.
- Garcia RE, Moodie DS. Lipid profiles in hypercholesterolemic children. (Submitted for Publication 1990).
- Schieken RM. The management of the family at high risk for coronary heart disease. *Cardiol Clin* 1989; **7**:467-477.
- Consensus conference. Lowering blood cholesterol to prevent heart disease. *JAMA* 1985; **253**:2080-2086.
- Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. The expert panel. *Arch Int Med* 1988; **148**:36-69.
- American Academy of Pediatrics Committee on Nutrition. Prudent lifestyle for children: dietary fat and cholesterol. *Pediatrics* 1986; **78**:521-525.
- American Academy of Pediatrics Committee on Nutrition. Indications for cholesterol testing in children. *Pediatrics* 1988; **83**:141-142.
- Bricker JT, Schieken RM, Strong WB. Pediatric Preventive Cardiology Clinics. *Am J Dis Child* 1988; **412**:953-956.
- Nader PR, Taras HL, Sallis JF, Patterson TL. Adult heart disease prevention in childhood: a national survey of pediatricians' practices

and attitudes. *Pediatrics* 1987; **79**:843-850.

54. Strong WB, Dennison BA. Pediatric preventive cardiology: atherosclerosis and coronary heart disease. *Pediatr Rev* 1988; **9**:303-314.
55. West RJ. Problems of long-term treatment in children with familial hypercholesterolemia. *Prog Clin Biol Res* 1985; **118**:209-211.
56. Stein EA. Treatment of familial hypercholesterolemia with drugs in children. *Arteriosclerosis* **9**(suppl 1):145-151.
57. Colestipol therapy and selected vitamin and mineral levels in children. *Nutr Rev* 1980; **38**:236-237.
58. Rhoads GG, Gosta D, Berg K. Lp(a) lipoprotein as a risk factor for myocardial infarction. *JAMA* 1986; **256**:2540-2544.
59. Brunzell JD, Sniderman AD, Albers JJ, et al. Apoproteins B and A-I and coronary artery disease in humans. *Arteriosclerosis* 1984; **4**:79-83.
60. Freedman DS, Srinivasan SR, Shear CL, Franklin FA, Webber LS, Berenson GS. The relation of apolipoproteins A-I and B in children to parental myocardial infarction. *N Engl J Med* 1986; **315**:721-726.
61. US Preventive Services Task Force. Guide to clinical preventive services. Baltimore, MD: Williams and Wilkins; 1989.
62. Milton J. Paradise Lost. In: Ellidge S, ed. Critical Edition Series. New York: Norton Press; 1975:128-137.

